RoyTimothyWebbMD

PubMed

• 7 citations
  Trilaciclib dose selection: an integrated pharmacokinetic and pharmacodynamic analysis of preclinical data and Phase Ib/IIa studies in patients with extensive-stage sm...
  Chao Li, Lowell L. Hart, Taofeek K. Owonikoko, Raid Aljumaily, Caio Max Sao Pedro Rocha Lima, Paul Conkling, Roy Timothy Webb, Robert M. Jotte, Steven R. Schuster, Wil...> ;Cancer Chemotherapy and Pharmacology. 2021 Feb 17
• 108 citations
  Randomized Phase III Trial of Paclitaxel/Carboplatin With or Without PF-3512676 (Toll-Like Receptor 9 Agonist) As First-Line Treatment for Advanced Non–Small-Cell Lung...
  Vera Hirsh, Luis Paz-Ares, Michael Boyer, Rafael Rosell, Gary Middleton, Wilfried Eberhardt, Aleksandra Szczesna, Pavel Reiterer, Mansoor N. Saleh, Oscar Arrieta, Emil...> ;Journal of Clinical Oncology. 2011 Jul 1
• Incidence and risk factors of cetuximab-induced hypersensitivity infusion reactions (HIRs).
  Hopps S, Borders E, Medina P, Moorman M, Webb R, Kurkjian C, Pant S> ;J. Clin. Oncol.. 2011-05-20
• A phase II evaluation of the combination of paclitaxel protein-bound and carboplatin in the first-line treatment of advanced non-small cell lung cancer (NSCLC).
  Allerton JP, Hagenstad CT, Webb RT, Smith GB, Birch R, Goggins TF, Katakkar SB, Khan W, Mehta ND, Greco FA> ;J. Clin. Oncol.. 2006-06-20
• Randomized phase II study of the neurokinin 1 receptor antagonist CJ-11,974 in the control of cisplatin-induced emesis.
  Hesketh PJ, Gralla RJ, Webb RT, Ueno W, DelPrete S, Bachinsky ME, Dirlam NL, Stack CB, Silberman SL> ;J. Clin. Oncol.. 1999-01-01
• Join now to see all